Dipeptidyl peptidase-4 inhibitor/ja

DPP-4阻害薬とGLP-1

ジペプチジルペプチダーゼ4阻害薬（DPP-4 inhibitorまたはgliptins）は、経口血糖降下薬の一種であり、ブロック薬である。酵素ジペプチジルペプチダーゼ-4（DPP-4）を阻害する。これらは2型糖尿病の治療に使用できる。

このクラスの最初の薬物であるシタグリプチンは、2006年にFDAによって承認された。

グルカゴンは血糖値を上昇させ、DPP-4阻害薬はグルカゴンと血糖値を低下させる。DPP-4阻害薬の機序は、インクレチンレベル（GLP-1とGIP）を増加させ、グルカゴン放出を阻害し、その結果、インスリン分泌を増加させ、胃排出を減少させ、血糖値を低下させる。

2018年のメタアナリシスでは、2型糖尿病患者の全死亡、心血管死亡、心筋梗塞、脳卒中に対するDPP-4阻害薬の好ましい効果は認められなかった。

Examples

Drugs belonging to this class are:

• Sitagliptin (FDA approved 2006, marketed by Merck & Co. as Januvia)
• Vildagliptin (EU approved 2007, marketed in the EU by Novartis as Galvus)
• Saxagliptin (FDA approved in 2009, marketed as Onglyza)
• Linagliptin (FDA approved in 2011, marketed as Tradjenta by Eli Lilly and Company and Boehringer Ingelheim)
• Gemigliptin (approved in Korea in 2012, marketed by LG Life Sciences) Marketed as Zemiglo
• Anagliptin (approved in Japan as Suiny in 2012, marketed by Sanwa Kagaku Kenkyusho Co., Ltd. and Kowa Company, Ltd.)
• Teneligliptin (approved in Japan as Tenelia in 2012)
• Alogliptin (FDA approved 2013 as Nesina/ Vipidia, marketed by Takeda Pharmaceutical Company)
• Trelagliptin (approved for use in Japan as Zafatek/ Wedica in 2015)
• Omarigliptin (MK-3102) (approved as Marizev in Japan in 2015, developed by Merck & Co.; research showed that omarigliptin can be used as once-weekly treatment and generally well tolerated throughout the base and extension studies)
• Evogliptin (approved as Suganon/ Evodine for use in South Korea)
• Gosogliptin (approved as Saterex for use in Russia)
• Dutogliptin (PHX- 1149 free base, being developed by Phenomix Corporation), Phase III
• Retagliptin (SP-2086), approved in China.
• Denagliptin
• Cofrogliptin (HSK- 7653, compound 2)
• Fotagliptin
• Prusogliptin

Other chemicals which may inhibit DPP-4 include:

• Berberine, an alkaloid found in plants of the genus Berberis, inhibits dipeptidyl peptidase-4 which may at least partly explains its antihyperglycemic activity.

Adverse effects

In those already taking sulphonylureas, there is an increased risk of low blood sugar when taking a medicine in the DPP-4 drug class.

Adverse effects include nasopharyngitis, headache, nausea, heart failure, hypersensitivity and skin reactions.

The U.S. Food and Drug Administration (FDA) is warning that the type 2 diabetes medicines like sitagliptin, saxagliptin, linagliptin, and alogliptin may cause joint pain that can be severe and disabling. FDA has added a new Warning and Precaution about this risk to the labels of all medicines in this drug class, called dipeptidyl peptidase-4 (DPP-4) inhibitors. However, studies assessing risk of rheumatoid arthritis among DPP-4 inhibitor users have been inconclusive.

A 2014 review found increased risk of heart failure with saxagliptin and alogliptin, prompting the FDA in 2016 to add warnings to the relevant drug labels.

A 2018 meta analysis showed that use of DPP-4 inhibitors was associated with a 58% increased risk of developing acute pancreatitis compared with placebo or no treatment.

A 2018 observational study suggested an elevated risk of developing inflammatory bowel disease (specifically, ulcerative colitis), reaching a peak after three to four years of use and decreasing after more than four years of use.

A 2020 Cochrane systematic review did not find enough evidence of reduction of all-cause mortality, serious adverse events, cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke or end-stage renal disease when comparing metformin monotherapy to dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes.

Cancer

In response to a report of precancerous changes in the pancreases of rats and organ donors treated with the DPP-4 inhibitor sitagliptin, the United States FDA and the European Medicines Agency each undertook independent reviews of all clinical and preclinical data related to the possible association of DPP-4 inhibitors with pancreatic cancer. In a joint letter to the New England Journal of Medicine, the agencies stated that they had not yet reached a final conclusion regarding a possible causative relationship.

A 2014 meta-analysis found no evidence for increased pancreatic cancer risk in people treated with DPP-4 inhibitors, but owing to the modest amount of data available, was not able to completely exclude possible risk.

Combination drugs

Some DPP-4 inhibitor drugs have received approval from the FDA to be used with metformin concomitantly with additive effect to increase the level of glucagon-like peptide 1 (GLP-1) which also decreases hepatic glucose production.

See also

• Development of dipeptidyl peptidase-4 inhibitors